## **Budget Update**

NIH Director's Report to the Advisory Committee to the Director December 14, 2017

Neil K. Shapiro Associate Director for Budget, NIH





## **FY 2018 So Far**

- Currently under the second Continuing Resolution
  - First through December 8, 2017
  - Second through December 22, 2017
  - Third is likely into January 2018
  - Funding level is FY 2017 enacted, including 21<sup>st</sup> Century Cures Act's Innovation projects, less 0.6791 percent
- Progress on an FY 2018 Omnibus bill awaiting decisions on subcommittee allocations
- Type 1 Diabetes mandatory funding (\$150 million) not yet reauthorized for FY 2018, but two-year extension proposed in H.R. 3922 (passed House on November 3)

## **Appropriations Action: House**

- FY 2018 bill voted out of Full Committee on July 24
- Level for NIH is \$1.1 billion above FY 2017 enacted, including full funding of 21st Century Cures Act's Innovation projects
- Targeted increases in bill, *e.g.*, Alzheimer's disease (\$400 million), BRAIN Initiative, Precision Medicine Initiative
- Does not accept proposed consolidations or indirect cost policy in the FY 2018 President's Budget

## **Appropriations Action: Senate**

- FY 2018 bill voted out of Full Committee on September 7
- Funding level for NIH is \$2 billion above FY 2017 enacted, including full funding of 21st Century Cures Act's Innovation projects
- Targeted increases in bill, *e.g.*, Alzheimer's disease (\$414 million), BRAIN Initiative, Precision Medicine Initiative, Antimicrobial resistance
- Does not accept proposed consolidations or indirect cost policy in the FY 2018 President's Budget